Lopurin and Primary myelofibrosis - a phase IV clinical study of FDA data

Summary:

Primary myelofibrosis is found among people who take Lopurin, especially for people who are male, 60+ old, have been taking the drug for 2 - 5 years.

The phase IV clinical study analyzes which people take Lopurin and have Primary myelofibrosis. It is created by eHealthMe based on reports of 164,084 people who have side effects when taking Lopurin from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On May, 04, 2023

164,084 people reported to have side effects when taking Lopurin.
Among them, 171 people (0.1%) have Primary myelofibrosis.

What is Lopurin?

Lopurin has active ingredients of allopurinol. It is often used in gout. eHealthMe is studying from 166,562 Lopurin users for its effectiveness, alternative drugs and more.

What is Primary myelofibrosis?

Primary myelofibrosis (primary disorder of the bone marrow) is found to be associated with 1,090 drugs and 769 conditions by eHealthMe.

Number of Lopurin and Primary myelofibrosis reports submitted per year:

Could Lopurin cause Primary myelofibrosis?

* Approximation only. Some reports may have incomplete information.

Do you take Lopurin and have Primary myelofibrosis?

Check whether Primary myelofibrosis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Primary myelofibrosis and when was it recovered:

Primary myelofibrosis in Lopurin

Expand to all the drugs that have ingredients of allopurinol:

Primary myelofibrosis and drugs with ingredients of allopurinol (172 reports)

Alternative drugs to, pros and cons of Lopurin:

Lopurin (166,562 reports)

Common Lopurin side effects:

Diarrhea: 9,704 reports
Fatigue (feeling of tiredness): 9,573 reports
Breathing difficulty: 9,370 reports
Weakness: 8,160 reports
Fever: 8,051 reports
Pneumonia: 7,437 reports
Thrombocytopenia (decrease of platelets in blood): 7,369 reports

Browse all side effects of Lopurin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Primary myelofibrosis treatments and more:

Primary myelofibrosis (35,056 reports)

COVID vaccines that are related to Primary myelofibrosis:

Common drugs associated with Primary myelofibrosis:

All the drugs that are associated with Primary myelofibrosis:

Primary myelofibrosis (1,090 drugs)

Common conditions associated with Primary myelofibrosis:

High blood pressure: 141 reports
Idiopathic thrombocytopenic purpura (itp): 108 reports

All the conditions that are associated with Primary myelofibrosis:

Primary myelofibrosis (769 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on allopurinol (the active ingredients of Lopurin) and Lopurin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.